![]() Perceptive Advisors, funds and accounts advised by T. It was led by Avoro Ventures and Avoro Capital Advisors, along with OrbiMed Advisors and Andreessen Horowitz. 31, 2021 Scribe announced that it had raised $100 million in Series B financing. The contract also included tiered, high single-digit to sub-teen royalties. to develop and market CRISPR-based treatments for Amyotrophic Lateral Sclerosis (ALS), securing $15 million of funding upfront and a potential $400 million in future development and commercial milestone payments. 7, 2020, Jennifer Doudna along with Emmanuelle Charpentier won the Nobel Prize in Chemistry for their creation of CRISPR-Cas9 gene editing.Īs part of the Series A financing, Scribe entered into a research partnership with Biogen Inc. The company kept a low profile until it announced raising $20 million in series A financing led by Andreessen Horowitz on Oct. Scribe Therapeutics claims that modifications can be made to nearly any cell therapy product. Hematopoietic disorders: Sickle cell disease (SCD), severe combined immunodeficiency (SCID), Fanconi anemia (FA), hemophilia A/B, chronic granulomatous disease (CGD), and Von Willebrand disease.Ĭell therapy: CAR-T, NK, TiL, HSC, iPSC, and more. Multisystem, muscle & metabolic: Cystic fibrosis, Duchenne muscular dystrophy (DMD), myotonic dystrophy (DM), limb-girdle muscular dystrophy (LGMD), TTR amyloidosis, alpha-1 antitrypsin deficiency (A1AD), familial hypercholesterolemia, tyrosinemia, phenylketonuria, acute intermittent porphyria (AIP), hypertriglyceridemia, Hutchinson-Gilford progeria syndrome (HGPS), methylmalonic acidemia, propionic acidemia, and primary hyperoxaluria. ![]() Ophthalmological diseases: Retinitis pigmentosa (RP), cone-rod dystrophy (CRD), Leber's congenital amaurosis, hereditary optic atrophy (HOA), Stargardt disease, choroideremia, glaucoma, best vitelliform macular dystrophy (BVMD), achromatopsia, and usher syndrome. Neurological diseases: Huntington's disease (HD), familial amyotrophic lateral sclerosis (familial ALS), spinal muscular atrophy (SMA), spinocerebellar ataxia (SCA), early-onset familial Alzheimer’s disease, Parkinson's disease, progressive supranuclear palsy (PSP), Dravet syndrome, Angelman syndrome, Friedrich ataxia, and Batten disease. Topic sponsors are not involved in the creation of editorial content.Įnter your details here to receive the free whitepaper.Disease & disorder treatment and cell therapy In August, the company signed a strategic and exclusive research collaboration with Atomwise to use the latter’s AtomNet platform for discovering and researching up to five drug targets computationally.Ĭell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.Įditorial content is independently produced and follows the highest standards of journalistic integrity. “This collaboration with Scribe complements our robust research efforts across the NK cell therapy spectrum and offers our scientists unique access to engineered CRISPR-based technologies as they strive to deliver off-the-shelf NK cell therapies and novel combination approaches that improve upon the first generation of cell therapies.” Sanofi Research global head and chief scientific officer Frank Nestle said: “At Sanofi, we are pushing the boundaries of science by developing a diverse range of next-generation therapies based on natural killer (NK) cells, which could have broad applications across solid tumours and blood cancers. Scribe’s CasX-Editors (XE), a suite of custom engineering genome editing and delivery tools based on new foundations such as the CasX enzyme, will back Sanofi’s developing NK cell therapies pipeline for cancer.
0 Comments
Leave a Reply. |